Hepatic hemangioma is a relatively common benign tumor of the liver, clinically cavernous hemangioma is the most common, with a natural population autopsy detection rate of 0.35-7.3%, accounting for 5-20% of benign liver tumors, and the literature reports a population incidence of about 5-7%. Hepatic hemangioma can develop at any age, but it is more common in 30-50 years old. Most hepatic hemangiomas have no obvious symptoms and are detected during routine ultrasound examinations or abdominal surgery. There is no evidence that they are malignant, but they can occasionally be confused with other malignant tumors of the liver, leading to misdiagnosis. When the hemangioma grows larger than 5 cm, nonspecific abdominal symptoms may occur, including: (1) abdominal mass (2) gastrointestinal symptoms (3) compression symptoms (4) hepatic hemangioma rupture and bleeding, which may present with severe upper abdominal pain, as well as bleeding and shock symptoms, and is one of the most serious complications. (5) Kasabach-Merritt syndrome, which is a hemangioma accompanied by thrombocytopenia, depletion of coagulation factors, causing abnormal coagulation mechanism, may further develop into DIC. (6) Others: When a tipped hemangioma growing outside the liver is twisted, necrosis may occur, and severe abdominal pain, fever and deficiency may occur. There are also individual patients with huge hemangioma with arteriovenous fistula formation, resulting in increased return blood volume and increased burden on the heart, leading to heart failure and death. There are also rare cases of biliary hemorrhage. Hepatic hemangioma lacks specific clinical manifestations, and imaging examinations (such as ultrasound, CT, MRI) are currently the main methods for diagnosing hepatic hemangioma. Comprehensive literature reports suggest that the diagnosis rate of hepatic hemangioma is 57.0%-90.5% for ultrasound, 73.0%-92.2% for CT, 84.0-92.7% for MRI, and 62.5% for hepatic arteriography. There is a great controversy on the treatment of hepatic hemangioma, mainly including hemangioma resection, hemangioma suture, hepatic artery ligation, microwave curing, radiofrequency treatment, hepatic artery embolization, etc. For diffuse hepatic hemangiomas or huge hemangiomas that cannot be removed, such as hepatic dysfunction or combined with Kasabach?Merritt syndrome, liver transplantation is also feasible. For hepatic hemangioma requiring treatment, a variety of factors should be considered, and different treatment modalities should be selected based on the principle of patient benefit, safety, and effectiveness, weighing multiple factors according to the skill level and experience of the physician. Surgical resection of hepatic hemangioma is reliable and safe, and complete resection is the only method that can cure it. With the development of surgical techniques, the incidence of surgery-related complications and mortality rates are now very low. Nevertheless, the indications for surgery still need to be strictly controlled. Common surgical procedures include hepatic segmental resection, hemangioma debulking, laparoscopic hepatectomy, hemangioma suturing, and liver transplantation. Currently, it is considered that: (1) right liver >8cm, left liver and caudate lobe >6cm, with clear symptoms or exophytic or growth rate >1-2cm/year; (2) hemangioma diameter >10cm; (3) complications such as infection and fever, bleeding and obvious hematological abnormalities; (4) for patients older than 60 years old, the indications should be more stringent because the hemangioma may not grow anymore or grow slower; (5) for patients older than 60 years old, the indications should be more strict. (5) In view of the fact that hepatic hemangioma may increase faster during pregnancy and may cause rupture and hemorrhage during delivery, the huge hepatic hemangioma in young women should be actively surgically removed; (6) For those who are engaged in strenuous sports, such as boxers and soccer players, surgical removal can be considered; (7) If the tumor is found to grow faster during the follow-up, other lesions cannot be excluded. Clear clinical symptoms, exophytic nature, rapid growth rate and concomitant hematological abnormalities should be the indications for surgery in such patients. Among the treatments for hepatic hemangiomas, debulking is significantly better than resection in terms of safety, completeness, bleeding, blood transfusion, and length of hospital stay, and only slightly higher than resection in terms of the occurrence of biliary leakage, but there is no statistical difference. Some hemangiomas that cannot be removed by resection can be completely debulked by exenteration. In some hemangiomas located in the margin, exophytic, and left hepatic outer lobe, laparoscopic resection can be applied for the purpose of less trauma and faster recovery. In conclusion, the diagnosis and treatment of hepatic hemangioma are progressing, and as a common and frequent disease of the liver, clinical attention should be paid to it, and the treatment should be cautious and strict, and attention should be paid to differentiate it from other lesions of the liver, especially malignant diseases.